Dapagliflozin / Ramipril (Egis Pharmaceuticals)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameDapagliflozin / Ramipril (Egis Pharmaceuticals)
Drug Alias Namedapagliflozin + ramipril
ClassificationSmall molecules
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitorsAngiotensin-converting enzyme inhibitors
TargetsAngiotensin-converting enzymeSodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2Renal Insufficiency, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryEU
CombinationsYes
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEgis Pharmaceuticals PLC
China Registration ClassN/A

Develop Information

Active CompaniesEgis Pharmaceuticals PLC
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Renal Insufficiency, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A